How it's calculated
Treatment dosing is 1 mg/kg every 12 hours (or 1.5 mg/kg once daily for uncomplicated outpatient DVT); prophylactic dosing is a flat 40 mg once daily (30 mg twice daily for higher-risk orthopaedic surgery). CrCl below 30 mL/min reduces both regimens, per the manufacturer's renal dose adjustment.
Renal dose adjustment (CrCl < 30 mL/min)
| Indication | Standard dose | CrCl < 30 mL/min |
|---|---|---|
| Treatment | 1 mg/kg every 12 hours | 1 mg/kg once daily |
| Prophylaxis | 40 mg once daily | 30 mg once daily |
Clinical use
- Used for VTE treatment (DVT/PE) and prophylaxis in medical and surgical inpatients, and for bridging anticoagulation around procedures.
- Anti-Xa level monitoring may be used to guide dosing in renal impairment, obesity, or pregnancy, where the standard weight-based dose is less predictable.
- Not routinely reversed by protamine to the same degree as unfractionated heparin — only partially neutralises LMWH anti-Xa activity.
Frequently asked questions
What's the difference between enoxaparin treatment and prophylactic dosing?
Treatment dosing (1 mg/kg twice daily) is used for confirmed or highly suspected VTE; prophylactic dosing (40 mg once daily) is a much lower, fixed dose used to prevent VTE in at-risk hospitalised patients — they are not interchangeable.
Why does renal function matter so much for enoxaparin?
Enoxaparin is renally cleared, so reduced kidney function leads to drug accumulation and a higher bleeding risk — dosing is reduced at a CrCl below 30 mL/min, and some clinicians favour unfractionated heparin (more easily reversible and not renally dependent) in severe renal impairment.
Can enoxaparin be used in pregnancy?
Yes, it's commonly used for VTE prophylaxis and treatment in pregnancy, but dosing may need adjustment across trimesters as weight and clearance change — anti-Xa monitoring is often used to guide therapeutic dosing in pregnancy.
References
- Lovenox (enoxaparin) Prescribing Information, Sanofi-Aventis.
- Garcia DA, et al. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP Guidelines. Chest. 2012.